Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study

BACKGROUND: Additional forms of pre-exposure prophylaxis are needed to prevent HIV-1 infection. 3BNC117 and 10–1074 are broadly neutralizing anti-HIV-1 antibodies that target non-overlapping epitopes on the HIV-1 envelope. We investigated the safety, tolerability, pharmacokinetics, and immunogenicit...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Yehuda Z., Butler, Allison L., Millard, Katrina, Witmer-Pack, Maggi, Levin, Rebeka, Unson-O’Brien, Cecilia, Patel, Roshni, Shimeliovich, Irina, Lorenzi, Julio C. C., Horowitz, Jill, Walsh, Stephen R., Lin, Shu, Weiner, Joshua A., Tse, Anna, Sato, Alicia, Bennett, Chelsey, Mayer, Bryan, Seaton, Kelly E., Yates, Nicole L., Baden, Lindsey R., deCamp, Allan C., Ackerman, Margaret E., Seaman, Michael S., Tomaras, Georgia D., Nussenzweig, Michel C., Caskey, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687118/
https://www.ncbi.nlm.nih.gov/pubmed/31393868
http://dx.doi.org/10.1371/journal.pone.0219142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687118/
https://www.ncbi.nlm.nih.gov/pubmed/31393868
http://dx.doi.org/10.1371/journal.pone.0219142

Ejemplares similares